LOGIN  |  REGISTER
Amneal Pharmaceuticals
Assertio

Elutia to Participate in Upcoming Investor Conferences

September 03, 2024 | Last Trade: US$1.81 0.09 5.23

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:

H.C. Wainwright 26th Annual Global Investment Conference
Format: Presentation and 1x1 Meetings
Presentation Date and Time (On-demand beginning): Monday, September 9, 2024, 7:00 a.m. ET
1x1 Meetings: Wednesday, September 11, 2024
Webcast: Click here

Lake Street Capital Markets 8th Annual Best Ideas Growth Conference
Format: 1x1 Meetings
Date: Thursday, September 12, 2024

Institutional investors interested in meeting with management during the conferences may reach out to their respective H.C. Wainwright and Lake Street representatives.

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page